Trospium chloride/xanomeline - Karuna Therapeutics
Alternative Names: BMS-986510; COBENFY; Karuna-Xanomeline-Trospium - Karuna Therapeutics; KarXT - Karuna Therapeutics; Trospium chloride/LY-246708 - Karuna Therapeutics; Trospium chloride/xanomeline tartrate - Karuna Therapeutics; Xanomeline tartrate/ trospium chloride - Karuna Therapeutics; Xanomeline/trospium chloride - Karuna TherapeuticsLatest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator PureTech Health
- Developer Karuna Therapeutics; ZAI Lab
- Class Analgesics; Antidementias; Antipsychotics; Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Pyridines; Small molecules; Spiro compounds; Thiadiazoles; Urologics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Schizophrenia
- Phase III Psychotic disorders
- Discontinued Pain